What Is Thymosin Beta-4 (Tβ4)?

Thymosin beta-4 (Tβ4) is a naturally occurring peptide of 43 amino acids found in nearly every cell type. It is best characterized in research as an actin-sequestering peptide, and it is the molecule most often referenced — and most often confused with — the market name TB-500. It is not an approved drug.

The short answer

Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian tissue. Despite the "thymosin" name, it is not primarily a thymic hormone: it was first isolated from a thymic extract in 1981, but it is present across nearly all tissues and body fluids, and its defining activity is the regulation of actin. In a research context it is supplied as a lyophilized powder and verified by mass spectrometry and HPLC before use. Human clinical evidence remains limited, and it has not been approved by the FDA for any use.

Sequence and structure

Thymosin beta-4 is a single chain of 43 amino acids with an N-terminally acetylated serine. It is the most abundant member of the beta-thymosin family, encoded in humans by the TMSB4X gene. The published human sequence is:

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

The single methionine at position 6 is worth noting for handling: it can oxidize, and in the research literature the oxidized (sulfoxide) form shows reduced actin-binding activity — one practical reason peptides like this are kept cold, dry, and protected from air. See peptide handling and storage for the general reasoning.

What it does: actin sequestration

The best-established role of thymosin beta-4 is as the primary intracellular G-actin-sequestering peptide. It binds monomeric (globular) actin in a roughly 1:1 complex, holding a reserve of actin subunits and thereby regulating how much is available to polymerize into filaments (F-actin). Because actin filament assembly underlies cell shape, motility, and directed migration, Tβ4 sits upstream of a wide set of cytoskeletal processes. This actin-buffering function was established when the peptide was shown to be identical to "Fx," an actin-sequestering factor previously isolated from platelets.

These are descriptions of the peptide's molecular biology as characterized in the laboratory — not claims that administering it produces any particular outcome in a person.

Thymosin beta-4 vs. TB-500

This is the point most product listings get wrong, so it is worth stating carefully. Thymosin beta-4 is the full, naturally occurring 43-amino-acid peptide described above. TB-500 is a name used in the research-chemical market, and it is frequently — but not always — used to refer to the same full-length molecule; some references instead describe TB-500 as a shorter fragment corresponding to the peptide's actin-binding region. In practice the two names are used loosely and interchangeably across vendors.

Rather than assert one definition, the accurate approach is to defer to the analytical data: the identity of any given vial is settled by its mass-spectrometry value. Full-length thymosin beta-4 lands near ~4.9 kDa; a short actin-binding fragment would be far lighter. That is why an independent, batch-specific Certificate of Analysis — not the label — is the thing that tells a researcher which molecule they actually have. Our companion overview covers this from the TB-500 side: What Is TB-500?

What has research examined?

Beyond actin sequestration, thymosin beta-4 is described in the literature as a "moonlighting" peptide — one molecule associated with several distinct activities. Preclinical (animal and cell-based) research has investigated Tβ4 in areas including:

• Cell migration and cytoskeletal dynamics
• Tissue-repair and wound-healing models
• Angiogenesis (blood-vessel formation) signaling
• Inflammation-related pathways

As with any research peptide, these represent directions that have been studied, largely in non-human models. They are not established human effects, and the distance between preclinical signals and demonstrated clinical outcomes is substantial.

How it is characterized and tested

Research-grade thymosin beta-4 is verified the same way as any peptide: identity confirmed by mass spectrometry (does the measured mass match the expected value for the sequence?) and purity measured by HPLC, with both reported on a Certificate of Analysis. Because this molecule is so often conflated with TB-500, the mass-spec figure is doubly important here — it is what distinguishes full-length Tβ4 from a fragment. A published, batch-specific COA from an independent lab lets a researcher confirm both identity and purity before beginning work.

Common questions

Is thymosin beta-4 the same as TB-500?

Not exactly. Thymosin beta-4 is the full 43-amino-acid peptide; TB-500 is a market name usually associated with an active portion of that sequence, though usage varies. The mass-spec value on the Certificate of Analysis is what confirms which molecule is in a given vial.

What does thymosin beta-4 do in the body?

Its best-characterized role is binding and sequestering G-actin, which regulates actin polymerization and cytoskeletal dynamics. This is a laboratory description of its biology, not a claim about any effect from supplementation.

Is thymosin beta-4 approved for human use?

No. It is not an FDA-approved drug and is studied in research settings only.

References

• Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4. Proc Natl Acad Sci USA. 1981;78(2):1162–1166. PMID 6940133
• Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032. PMID 1999398
• Sanders MC, Goldstein AL, Wang YL. Thymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci USA. 1992;89(10):4678–4682. PMID 1584803
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. PMID 22074294